Diabetes is a fast growing metabolic disease, where the patients suffer from disordered glucose blood levels. Monitoring the blood glucose values in combination with extra insulin injection is currently the only therapy to keep the glucose concentration in diabetic patients under control, minimizing the long-term effects of elevated glucose concentrations and improving quality of life of the diabetic patients. Implantable sensors allow continuous glucose monitoring, offering the most reliable data to control the glucose levels. Infrared absorption spectrometers offer a non-chemical measurement method to determine the small glucose concentrations in blood serum. In this work, a spectrometer platform based on silicon photonics is presented, allowing the realization of very small glucose sensors suitable for building implantable sensors. A proof-of-concept of a spectrometer with integrated evanescent sample interface is presented, and the route towards a fully implantable spectrometer is discussed.
INTRODUCTION
Diabetes is a fast growing metabolic disease, where patients have an elevated glucose concentration. The number of diabetic patients worldwide is estimated at 347 million in 2013 [1] . In healthy persons, insulin is released by the pancreas and controls the uptake of glucose by the cells. If the production of insulin is reduced, or if the cells become resistant to insulin, the uptake of glucose is disturbed, leading to multiple adverse effects for the patient: on short term, the glucose concentration is strongly fluctuating, resulting in very high or low glucose values. Hypoglycemia is an acute risk. If the average glucose concentration is large, this can lead to many problems, such as nerve damage, kidney or eye problems, heart disease and stroke.
Measuring the blood glucose values in combination with extra injection of insulin at moments of high glucose concentrations is required to keep the blood glucose concentration in normal limits. The reference method, however, is a hexokinase based method starting from the blood serum (after filtering the red blood cells). This offers the highest accuracy, but requires specialized equipment. A more practical method is the finger-prick method, where a small blood droplet is taken from the patient, put on a strip including dry chemistry for a glucoxidase enzymatic reaction. This reaction creates a small current proportional to the glucose concentration in the sample.
Implantable sensors offer more user comfort and allow for continuous glucose monitoring: the glucose is measured automatically, without need for user intervention such as finger pricking. Implantable sensors based on the enzymatic reaction are commercially available and FDA approved [2] , from different suppliers (Dexcom, MedTronics, Abbott). These sensors consist of a small probe that contains the chemistry for the enzymatic reaction, inserted under the skin in the subcutaneous region, and connected to a readout unit. The sensors are thus transdermal, partially under the skin, partially on top of the skin. The implantation period is limited to a couple of days (depending on the product). Two effects limit the maximal implantation time: the stability of the chemical reagents taking part in the enzymatic reaction, and the foreign body reaction to the by-products of the chemistry, resulting in an encapsulation of the probe.
Optical absorption spectroscopy is proposed as a method for glucose sensing as glucose has its own specific spectral features both in the first overtone band (1500-1800nm) and the combination band (2100-2400nm) [3] . However the glucose absorption spectrum is overlapping with the spectrum of water and other interfering substances in the interstitial fluid. Moreover, the glucose concentration is rather small in the serum (typically the glucose concentration in healthy persons is 80-200mg/dL, corresponding to 0.008-0.02 weight %), implying that the changes in the absorption spectrum mode is excited and thus the mode that feels the absorption by the sample on top of the waveguide. Glucose concentrations down to 1mM have been measured.
ABSORPTION SPECTROMETER MEASUREMENTS
Structures with waveguides for evanescent absorption spectrometry, coupled to on-chip spectrometer devices for measuring the absorption spectrum, were fabricated. Figure 6 shows the design of the fabricated devices. The response of the silicon photonics spectrometer is measured without and with liquid sample on the sensing spiral. The ratio of the two spectra is the transmission spectrum, as shown in figure 7 . Poly-ethylene Glycol (PEG) is used as test sample, as this substance has a specific absorption peak in the first overtone band at 1620nm, in the center of the spectrometer measurement range. The absorption spectrum measured is in agreement with the theoretical absorption spectrum of PEG. The spectrum is shown in figure 7 . The same approach can be used for evanescent glucose absorption spectroscopy as reported in [12] .
INTEGRATION OF LIGHT SOURCES IN THE SPECTROMETER
Silicon photonics spectrometers including photodiodes and sample interfaces have been demonstrated. As noticed in the introduction, the changes in the absorption spectrum due to glucose in clinical applications is very small. The principle of using evanescent light absorption to measure glucose concentration variations for measuring glucose is reported elsewhere [12] , showing the feasibility of this type of setup for measuring the ultra-small variations in the absorption spectrum corresponding to the changes of blood glucose in clinical applications. The last missing link is an integrated light source integrated on the chip. A broadband light source is required to illuminate the sample, either an ASE-source or a tunable laser or a multi-wavelength laser array. In this work a laser array is selected as light source, and two implementations are investigated. The integration of the laser on the silicon photonics is similar to the integration of photo diodes: the III/V epitaxy is adhesively bonded on the silicon photonics chip, the substrate is removed and the laser structures are defined lithographically in the remaining thin-film III/V layer on the silicon photonics chip.
Electrically pumped hybrid InGaAsSb-Si laser for the combination band
The laser is designed to have the optical mode divided between the Si waveguide and a gain region (In 0.67 Ga 0.33 As 0.08 Sb 0.92 quantum wells). Figure 8a illustrates the not-to-scale device schematically (not to scale). The 1D optical mode profile is presented in Figure 8b . With such an optical mode design, it allows an efficient light coupling from laser to Si waveguide. Moreover, it is possible to form a wavelength selective component such as a grating on Si to provide feedback to the laser cavity. Therefore, a single wavelength laser such as a DFB laser can be achieved with this design. Figure 8c presents the preliminary L-I measurement result of the hybrid InGaAsSb-Si Fabry-Perot laser. The laser operates up to 10°C in pulsed regime. The optical spectrum is shown in the inset. The wavelength emission is at ~2.4µm 
Electrically pumped hybrid InAlGaAs-Si laser for the first overtone band
We also developed a novel microlaser type based on heterogeneous integration of III-V materials onto the SOI circuit using adhesive bonding. The novel laser relies on resonant silicon grating cavities buried under the III-V laser mesa that act as narrow-band reflectors [13] . This approach allows for small, single mode laser devices that require low threshold power. Recently we demonstrated an optically pumped prototype of this device [14] . This laser is 55um long, requires ±2 mW threshold power and has a side-mode suppression ratio of 39 dB. An electrically pumped version of this laser is now being developed.
CONCLUSIONS
The development of a Silicon Photonics spectrometer platform for implantable glucose sensing applications is presented. The platform includes multi-wavelength light sources based on laser arrays, an evanescent analyte--interface, optical spectrometers and an array of thin-film bonded photodiodes. Spectrometer structures for spectral analysis of light centered round 1590nm and 2320nm is reported, covering the two spectral bands where the glucose absorption can be distinguished from the absorption of water and the other constituents in the blood serum. This work demonstrates the feasibility of ultra-small spectrometer systems, suitable for integration in a biocompatible package to realize a long-term implantable glucose sensor. This type of sensors will help diabetic patients in controlling their blood glucose values, improving their quality-of-life.
